SkyQuest Technology Group recently introduced Biosimilars Market study with in-depth overview, describing about the Product/Industry Scope and elaborates market outlook and status (2025-2032). The market Study is segmented by key regions which is accelerating the marketization. The Biosimilars Market has witnessed Excellent growth over the past decade and is expected to maintain its upward trajectory.
Biosimilars Market size was valued at USD 27.9 billion in 2023 and is poised to grow from USD 31.3 billion in 2024 to USD 88.9 billion by 2032, growing at a CAGR of 14.1% during the forecast period (2025-2032).
The global biosimilars market growth is mainly driven by the patent loss of biologic drugs as more affordable versions of the drug come up. For example, patent expiration of popular biologics such as Humira (adalimumab), Remicade (infliximab), and Herceptin (trastuzumab) has triggered the lift-off of biosimilar approvals and launches globally. This is translated to huge cost savings for patients and healthcare systems, as these are normally priced 15-30% cheaper than their reference biologics. Lower cost promotes increased adoption levels, particularly in markets that could not afford biologics prior to the present.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/biosimilars-market
One of the driving factors for biosimilars industry is support from regulatory agencies and streamlined approval procedures such as Biologics Price Competition and Innovation Act (BPCIA) and 351(k) Biologics License Application (BLA). As a response to increasing demand for affordable biologic substitutes, agencies such as the U.S. FDA, European Medicines Agency (EMA), and the WHO have created regulatory frameworks to make biosimilar approval quicker and more efficient.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Biosimilars Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
The global biosimilars market is segmented by Drug Class, Indication, Distribution Channel and region.
Based on Drug Class, the market is segmented into Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Insulin, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Interferons, Anticoagulants and Other Drug Classes.
Based on Indication, the market is segmented into Oncology, Inflammatory & Autoimmune Diseases, Chronic Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases and Other Indications.
Based on Distribution Channel, the market is segmented into Online Pharmacies, Hospital Pharmacies and Retail Pharmacies. Based on region, the biosimilars market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Biosimilars Market – Regional Analysis:
North America continues to lead the global biosimilars market share, driven by a robust regulatory framework, significant R&D investments, and a surge in biosimilar approvals. In 2024, the U.S. Food and Drug Administration (FDA) approved 18 new biosimilars, reflecting the region’s dynamic landscape for biosimilar therapies. The market is further bolstered by strategic shifts from major pharmacy benefit managers (PBMs) like UnitedHealth and CVS Health, which are increasingly favoring cost-effective biosimilars over branded biologics. This transition is expected to enhance patient access and drive substantial healthcare savings.
Europe is emerging as the fastest-growing region in the biosimilars market, propelled by favorable regulatory frameworks, increasing biosimilar adoption, and a strong presence of key market players. The European Medicines Agency’s (EMA) streamlined approval processes have facilitated the entry of numerous biosimilars, enhancing competition and driving down healthcare costs. The region’s commitment to biosimilar integration is evident in its robust market growth projections.
Top Market Players in Biosimilars Market are:
Sandoz
Biocon Biologics
Celltrion Healthcare
Amgen Inc.
Pfizer Inc.
Samsung Biologics
Viatris
Teva Pharmaceutical Industries
Fresenius Kabi
Coherus BioSciences
Alvotech
STADA Arzneimittel AG
Reliance Life Sciences
Dr. Reddy’s Laboratories
Novartis AG
Formycon AG
Intas Pharmaceuticals
BIOCAD
mAbxience
Apotex Inc
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/biosimilars-market
Recent Developments in Biosimilars Market:
In December 2024, Biocon Biologics received U.S. FDA approval for Yesintek (ustekinumab-kfce), a biosimilar for chronic inflammatory conditions like plaque psoriasis and Crohn’s disease. The approval strengthens Biocon’s presence in the U.S. market, providing an affordable option to branded biologics, and solidifying the company’s position in making global biosimilar accessibility and affordability.
In October 2024, Accord Healthcare had the European Medicines Agency (EMA) approve its biosimilar Imuldosa (ustekinumab-srlf). This biosimilar is indicated for the treatment of chronic inflammatory diseases, such as plaque psoriasis and Crohn’s disease. The approval reinforces Accord Healthcare’s position in the Europe biosimilars market, driving competition and broadening treatment access for patients.
In September 2024, Fresenius Kabi gained EMA approval for Otulfi (ustekinumab-aauz), a biosimilar of plaque psoriasis, psoriatic arthritis, and Crohn’s disease. The milestone enhances the company’s biosimilar portfolio in Europe, enhancing competition and affordability of critical biologic therapies, favoring patients suffering from autoimmune and inflammatory diseases.
Take Action Now: Secure Your Biosimilars Market Today – https://www.skyquestt.com/buy-now/biosimilars-market
Forward-Looking Insights
The Biosimilars Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
